NDAORALTABLET
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
E-Z-DISK (barium sulfate) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2025.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
E-Z-DISK is an oral tablet formulation of barium sulfate, a radiographic contrast agent used to visualize the gastrointestinal tract during X-ray imaging. It works by absorbing X-rays to create contrast in radiographic images, enabling clinicians to assess esophageal, gastric, and bowel anatomy. The tablet form offers convenient administration compared to liquid barium suspensions.
Launch
As a newly approved launch-stage product, E-Z-DISK represents early commercial build with opportunities for field sales, market access, and brand establishment teams.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Career Relevance
E-Z-DISK is a launch-stage specialty diagnostic product within a mature, consolidated market. Career opportunities center on market access, rapid portfolio integration, and competitive positioning against established Bracco products and GE HealthCare alternatives.
Brand Manager
Worked on E-Z-DISK at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.